Both. The Australian market tends to undervalue pre-revenue biotech companies and overvalue post-revenue biotechs, but there are lots of exceptions.
Both. The Australian market tends to undervalue pre-revenue...
-
- There are more pages in this discussion • 1,456 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
0.000(0.00%) |
Mkt cap ! $289.7M | |||
| Open | High | Low | Value | Volume |
| $1.70 | $1.70 | $1.66 | $85.03K | 50.83K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 21581 | $1.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.70 | 4979 | 4 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |